Fetrasil Taj Pharma

    India  | Taj Pharma Group | Worldwide  |  FAQ's   |  Exercise  |  Dieting  Health Tips  |  Help | Contact Us
Fetrasil™ Tablets,Sibutramine,herbal weight loss, sibutramine hydrochloride monohydrate,childhood obesity,teenage besity,obesity statistics,obesity diet,obesity children,obesity child,obesity causes,obesity exercise,obesity,overweigh
FETRASIL® (sibutramine HCl monohydrate)

India flag

Taj Pharmaceuticals Ltd.  
 You are here: Home Product Detail 

Health Fetrasil™

About Us     |     Product Portfolio    |     Fetrasil Brand    |    News    |     Export Quality    |    Contact Us  

 
 
home
   arrow Home
   down arrow About Us
   down arrow Product Profile
   down arrow Pharmaceuticals Brand
   down arrow Brand Manufacturing
   down arrow Product Details
   down arrow Fetrasil Usage
   down arrow Side Effects
   down arrow Warnings
   down arrow Dosages
   down arrow Fetrasil Gallery
   down arrow Description
   down arrow Warnings
   down arrow Clinical Pharmacology
   down arrow Indications
   down arrow Contraindications
   down arrow Precautions
   down arrow Patients
   down arrow Quality
   down arrow Feed Back
   down arrow Research Taj Pharma
   down arrow Other Products
   down arrow Site Map

  Other resources
  MSDSs
  Distributors
  Order Terms
Printed Catalog
  Analysis Tools
 


welcome

obesity topbanner

sibutramine hydrochloride

              Each Fetrasil Tablets contains 5 mg, 10 mg, and 15 mg of sibutramine hydrochloride monohydrate. It also contains as inactive ingredients: lactose monohydrate, NF; microcrystalline cellulose, NF; colloidal silicon dioxide, NF; and magnesium stearate, NF in a hard-gelatin Tablets
[which contains titanium dioxide, USP; gelatin; FD&C Blue No. 2 (5- and 10-mg Tabletss only)FETRASIL® (sibutramine HCl monohydrate)

              Fetrasil is indicated for the management of obesityFetrasil is indicated for the management of obesity, including weight loss and maintenance of weight loss, and should be used in conjunction with a reduced calorie diet. Fetrasil is recommended for obese patients with an initial body mass index ≥ 30 kg/m2, or ≥ 27 kg/m2 in the presence of other risk factors (e.g., diabetes, dyslipidemia, controlled hypertension).

handsDOSAGE AND ADMINISTRATION
The recommended starting dose of Fetrasil is 10 mg administered once daily with or without food. If there is inadequate weight loss, the dose may be titrated after four weeks to a total of 15 mg once daily. The 5 mg dose should be reserved for patients who do not tolerate the 10 mg dose. Blood pressure and heart rate changes should be taken into account when making decisions regarding dose titration (see WARNINGS and PRECAUTIONS).

Doses above 15 mg daily are not recommended. In most of the clinical trials, Fetrasil was given in the morning.

storageStorage
Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP controlled room temperature]. Protect Tabletss from heat and moisture. Dispense in a tight, light-resistant container as defined in USP.

warningWARNINGS
Blood Pressure and Pulse


Fetrasil SUBSTANTIALLY INCREASES BLOOD PRESSURE AND/OR PULSE RATE IN SOME PATIENTS. REGULAR MONITORING OF BLOOD PRESSURE AND PULSE RATE IS REQUIRED WHEN PRESCRIBING Fetrasil.

obesity childhood



PRECAUTIONS
Pulmonary Hypertension

Certain centrally-acting weight loss agents that cause release of serotonin from nerve terminals have been associated with pulmonary hypertension (PPH), a rare but lethal disease. In premarketing clinical studies, no cases of PPH have been reported with sibutramine Tabletss. Because of the low incidence of this disease in the underlying population, however, it is not known whether or not Fetrasil may cause this disease.
Seizures

During premarketing testing, seizures were reported in < 0.1% of sibutramine treated patients. Fetrasil should be used cautiously in patients with a history of seizures. It should be discontinued in any patient who develops seizures.
Bleeding

There have been reports of bleeding in patients taking sibutramine. While a causal relationship is unclear, caution is advised in patients predisposed to bleeding events and those taking concomitant medications known to affect hemostasis or platelet function.

Presentation
Loravan Tablets Blister of 10 Tablets


Note : This product information is intended only for residents of the India. Taj Pharmaceuticals Limited, medicines help to treat and prevent a range of conditions—from the most common to the most challenging—for people around the world.
 

 

obesity bottom banner

 

 
right arrow Fat people blamed for global warming
right arrow Stay slim to save the
planet
right arrow Fat people can get cancer easier
right arrow Fat people turn kids off junk food
right arrow Fat People Have a Higher Risk of Getting Diabetes than Thin People

obesity

chlestrol


big people

Research    |     Careers   |     Feed Back    |   Enquiry   |    Contact Us

Sitemap | User Terms and Conditions | Privacy and Cookie Statement
The products discussed herein may have different product labeling in different countries. The product information
provided in this site is intendedonly for the residents of India.
Copyright © 2009 Taj Pharmaceuticals Ltd. All rights reserved.
Click To Bookmark This Page ! |
Feed Back | Legal and Privacy Statement